Benefits of weight loss of 10% or more in patients with overweight or obesity: A review
This doesnt mean you have to rely on medication forever
It is worth mentioning that China's FDA said that the application for a marketing license for LIR injection for obesity or overweight indications had been accepted, which was the first time that the weight control indications of GLP-1R agonists have been accepted in China
From Medicaid data publicly available, there is no way yet to disentangle how much of the growing use of GLP-1s is related to treatment for diabetes, cardiovascular disease, or sleep apnea versus obesity, or a combination
Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M
The most detailed population-level analysis comes from Wharton et al., published in Diabetes, Obesity and Metabolism in 2021, which pooled data from the STEP 13 trials